Switch theme
Sign up to access all valuation multiples
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
2017
30
LTM Revenue $49.0M
LTM EBITDA $5.1M
$383M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eton Pharmaceuticals has a last 12-month revenue of $49.0M and a last 12-month EBITDA of $5.1M.
In the most recent fiscal year, Eton Pharmaceuticals achieved revenue of $39.0M and an EBITDA of -$1.5M.
Eton Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eton Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $31.6M | $39.0M | XXX | XXX | XXX |
| Gross Profit | $14.3M | $21.1M | XXX | XXX | XXX |
| Gross Margin | 45% | 54% | XXX | XXX | XXX |
| EBITDA | -$0.3M | -$1.5M | XXX | XXX | XXX |
| EBITDA Margin | -1% | -4% | XXX | XXX | XXX |
| Net Profit | -$9.0M | -$0.9M | XXX | XXX | XXX |
| Net Margin | -29% | -2% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eton Pharmaceuticals's stock price is $14.
Eton Pharmaceuticals has current market cap of $368M, and EV of $383M.
See Eton Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $383M | $368M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eton Pharmaceuticals has market cap of $368M and EV of $383M.
Eton Pharmaceuticals's trades at 7.8x LTM EV/Revenue multiple, and 74.5x LTM EBITDA.
Analysts estimate Eton Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eton Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $383M | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | -263.9x | XXX | XXX | XXX |
| P/E | -96.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -42.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEton Pharmaceuticals's NTM/LTM revenue growth is 73%
Eton Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Eton Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eton Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eton Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 399% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 69% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 58% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 67% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eton Pharmaceuticals acquired XXX companies to date.
Last acquisition by Eton Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Eton Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eton Pharmaceuticals founded? | Eton Pharmaceuticals was founded in 2017. |
| Where is Eton Pharmaceuticals headquartered? | Eton Pharmaceuticals is headquartered in United States of America. |
| How many employees does Eton Pharmaceuticals have? | As of today, Eton Pharmaceuticals has 30 employees. |
| Who is the CEO of Eton Pharmaceuticals? | Eton Pharmaceuticals's CEO is Mr. Sean E. Brynjelsen. |
| Is Eton Pharmaceuticals publicy listed? | Yes, Eton Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Eton Pharmaceuticals? | Eton Pharmaceuticals trades under ETON ticker. |
| When did Eton Pharmaceuticals go public? | Eton Pharmaceuticals went public in 2018. |
| Who are competitors of Eton Pharmaceuticals? | Similar companies to Eton Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eton Pharmaceuticals? | Eton Pharmaceuticals's current market cap is $368M |
| What is the current revenue of Eton Pharmaceuticals? | Eton Pharmaceuticals's last 12-month revenue is $49.0M. |
| What is the current EBITDA of Eton Pharmaceuticals? | Eton Pharmaceuticals's last 12-month EBITDA is $5.1M. |
| What is the current EV/Revenue multiple of Eton Pharmaceuticals? | Current revenue multiple of Eton Pharmaceuticals is 7.8x. |
| What is the current EV/EBITDA multiple of Eton Pharmaceuticals? | Current EBITDA multiple of Eton Pharmaceuticals is 74.5x. |
| What is the current revenue growth of Eton Pharmaceuticals? | Eton Pharmaceuticals revenue growth between 2023 and 2024 was 23%. |
| Is Eton Pharmaceuticals profitable? | Yes, Eton Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
